Medically reviewed by Leah Ansell, MDMedically reviewed by Leah Ansell, MD Plaque psoriasis is the most common type of psoriasis. Plaques are pink/red, raised, thick, inflamed skin patches covered by ...

84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16 ICONIC-LEAD is the first ever Phase 3 ...

Psoriasis causes thick patches of skin called plaques that are dry and flaky. Dandruff usually comes and goes and can be caused by oily hair or irritants. Psoriasis is a chronic autoimmune disease and ...

Plaque psoriasis, also known as psoriasis vulgaris, is quite common. The condition affects approximately 1% to 2% of whites, usually presenting in the third to fourth decade of life. Men with mycosis ...

Takeda ( TSE:4502/NYSE:TAK) today announced positive topline results for the two pivotal Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib ...

ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess safety and efficacy of a systemic therapy in adolescents and adults simultaneously 84% of ...

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated ...